ROCKVILLE, Md., Oct. 27,
2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced that it will present data from the
ALTITUDE® clinical trial evaluating RGX-314 using
suprachoroidal delivery for the treatment of patients with diabetic
retinopathy at the Retina Society 55th Annual Scientific Meeting
taking place in Pasadena, CA, from
November 2-5, 2022.
The Company will host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for
the quarter ended September 30, 2022,
recent operational highlights and this interim data.
Data Presentation Details:
Title: Suprachoroidal Delivery of RGX-314 for Diabetic
Retinopathy: The Phase II ALTITUDE Study
Presenter: Lejla Vajzovic,
MD, FASRS, Associate Professor of Ophthalmology and Director of
Duke Vitreoretinal Fellowship Program, Vitreoretinal Surgery and
Disease, Department of Ophthalmology, Duke
University School of Medicine
Date/Time: Wednesday, November 2,
2022, 4:41 p.m. PT
The presentation will be available under the Presentations &
Publications page in the Media section of REGENXBIO's website,
www.regenxbio.com.
Earnings Call Webcast Details:
Listeners can register for the webcast via this link. Analysts
wishing to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
company's investor website approximately two hours after the call's
conclusion. Those who plan on participating are advised to join 15
minutes prior to the start time.
About REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene therapy. REGENXBIO's NAV
Technology Platform, a proprietary adeno-associated virus (AAV)
gene delivery platform, consists of exclusive rights to more than
100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.
REGENXBIO and its third-party NAV Technology Platform Licensees are
applying the NAV Technology Platform in the development of a broad
pipeline of candidates, including late-stage and commercial
programs, in multiple therapeutic areas. REGENXBIO is committed to
a "5x'25" strategy to progress five AAV Therapeutics from our
internal pipeline and licensed programs into pivotal-stage or
commercial products by 2025.
Contacts:
Dana
Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-3-to-discuss-third-quarter-2022-financial-results-recent-operational-highlights-and-interim-data-from-phase-ii-altitude-trial-of-rgx-314-for-the-treatment-of-diabetic-retinopathy-301660842.html
SOURCE REGENXBIO Inc.